Report of Foreign Issuer (6-k)
May 08 2018 - 6:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES
EXCHANGE ACT OF 1934
For
the Month of May 2018
Commission
File Number: 001-38104
IMMURON
LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street,
Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If
Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
IMMURON
LIMITED
EXPLANATORY
NOTE
Immuron Limited (the “Company”)
published an announcement (the “Public Notice”) to the Australian Securities Exchange on May 8, 2018 titled “IMC
Preclinical Study Reports Reduction in Colitis Symptoms”.
A copy of the Public Notice is attached as an
exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
IMMURON
LIMITED
|
|
|
|
|
|
|
Date:
May 8, 2018
|
By:
|
/s/
Peter Vaughan
|
|
|
Peter
Vaughan
|
|
|
Joint
Chief Financial Officer
|
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From May 2023 to May 2024